Cell Easy Appoints CDMO Expert Dr. Sebastien Ribault as Independent Board Director, to Accelerate Its Rapid Growth
11.5.2023 19:00:00 EEST | Business Wire | Press release
Cell-Easy SAS (“Cell-Easy”), a rapidly growing Contract Development and Manufacturing Organization (“CDMO”) that specializes in cell therapy, has appointed Dr. Sebastien Ribault, PhD, to its board of directors, to further accelerate its growth.
Cell-Easy is a leading contract development and manufacturing organization (CDMO) with a strong foothold in Good Manufacturing Practice (GMP) manufacturing services for immune cells (T, NK cells) and adult stem cells (MSCs, iPSCs). Since 2020, the company keeps expanding into genetically modified cells such as CAR-T and CAR-NK, while also broadening its service offerings of development and analytical services. To further accelerate its expansion plans and drive leadership in the immune cell therapy market, Cell-Easy is pleased to announce the appointment of Sebastien Ribault, PhD, to its board of directors.
Sebastien brings nearly three decades of executive leadership in the CDMO and biotechnology industries, including successful experience in end-to-end CDMO expansion. He began his career in the biotech field, at the gene specialist biotech Transgene, before moving to the instrumentation and CDMO industry. Most recently, Sebastien was Vice President & Head of Biologics and Viral Vector CDMO at Merck Life Science, where he demonstrated expertise in rapidly growing business units. Currently, Sebastien is the Chief Commercial Officer at Oxford Biomedica, a leading viral vector specialist, which is notably used in the generation of CAR-T and CAR-NK cell products.
Guillaume Costecalde, Co-Founder and President of Cell-Easy, said, “As we continue to scale our organization to meet the growing demand from clients, we are excited to welcome Sebastien to the team. With his proven track record in leading rapidly expanding CDMOs, he will provide strategic guidance to help Cell-Easy achieve market-leading status.”
Sebastien Ribault added, “I am delighted to join Cell-Easy’s Board of Directors at this exciting time for the company. Cell-Easy has already built an amazing team and successfully delivered on its core business in record time. I am excited to contribute to the company's journey as it continues to expand its services in cell therapy CDMO, with a focus on genetically modified cells and analytical services, building on its strong foundation and industry-leading expertise.”
With its focus on expanding its range of services and its experienced leadership team, Cell-Easy is well-positioned to continue its growth and success as a trusted partner for biotech and pharma companies looking to develop and manufacture innovative cell therapies.
About Cell-Easy
Cell-Easy takes pride in its proficiency in GMP manufacturing coupled with robust quality assurance and regulatory support to ensure successful process completion. Cell-Easy provides a range of services, in the manufacturing of qualified cell therapy products (T-cells, NK-cells, MSCs, iPSCs) and genetically modified cells (Car-T, CAR-NK) along with a broadened service catalogue of development and analytical services. Its relatively small team size enables it to adapt to the specific needs and preferences of clients.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230511005389/en/
Contact information
Media and Investor Contacts:
Emercell, Dr. Patrick Henno, President, patrick.henno@emercell.com, (+33)-6-14-77-39-21
Cell-Easy, Dr. Guillaume Lay, Business Development, Guillaume.lay@cell-easy.com, (+33)-6 15 18 13 13
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Yoshihiro Shimamura Joins the Marché du Film’s “Investors Circle 2026” as an Invited Investor, Backing a New Feature Film17.7.2026 04:00:00 EEST | Press release
Shimamura Yoshihiro Film Production Co., Ltd. (Head office: Osaka, Japan; Representative Director: Yoshihiro Shimamura), a company active in film production and investment, today announced that Representative Director Yoshihiro Shimamura has decided to invest in an international feature film after being invited to the “Investors Circle 2026” — a distinction that reflects his standing as one of the field’s most highly regarded producers and investors. Hosted by the Marché du Film, the business arm of the Festival de Cannes and one of the world’s largest film markets, the Investors Circle is an invitation-only summit that connects a select group of private investors with high-end feature films during early-stage financing. Held in Cannes, France, May 16-17, 2026, it brings internationally acclaimed directors and producers together with investors around a curated slate of projects in development. During the summit, Shimamura attended private pitching sessions and, after individual meeting
Meiji Seika Pharma: Results from the Global Phase III Trial (Integral-2) of Nacubactam, a Novel β-Lactamase Inhibitor, Highlighted in The Lancet Microbe ’s Coverage of ESCMID Global Congress 202617.7.2026 04:00:00 EEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, President and Representative Director: Toshiaki Nagasato) today announced that results from the global Phase III trial (Integral-2) of nacubactam (Development Code: OP0595), a novel β-lactamase inhibitor, were highlighted in The Lancet Microbe’s coverage of ESCMID Global Congress 2026 (held in Munich, Germany). As highlighted in The Lancet Microbe’s coverage, the key findings presented by Meiji Seika Pharma at ESCMID Global Congress 2026 are as follows: The Integral-2 study (jRCT2031230076) is a global Phase III clinical trial that enrolled patients with complicated urinary tract infections, acute uncomplicated pyelonephritis, hospital-acquired bacterial pneumonia, ventilator-associated bacterial pneumonia, or complicated intra-abdominal infections caused by carbapenem-resistant Gram-negative bacteria (excluding Acinetobacter species). The study has achieved the prespecified study objectives. For the primary endpoint of overall treatme
Takeda’s Zasocitinib Demonstrates Consistent, High Rates of Skin Clearance Across the Body, Including Hard-to-Treat and High-Impact Sites, in Phase 3 Psoriasis Studies17.7.2026 01:00:00 EEST | Press release
Takeda (TSE:4502/NYSE:TAK) announced new data from the two pivotal Phase 3 studies of zasocitinib (TAK-279), a next-generation, highly selective and potent oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented at the 2026 American Academy of Dermatology (AAD) Innovation Academy, these secondary endpoint data show that zasocitinib demonstrated consistent and high rates of skin clearance across hard-to-treat, high-impact sites, including the scalp, nails, palms and soles, compared with placebo.1-5 These data build on the topline results from the Phase 3 randomized, multicenter, double-blind, placebo- and active comparator-controlled LATITUDE PsO 3001 and 3002 studies.2,6 In those studies, about 70% of patients treated with zasocitinib achieved static Physician Global Assessment (sPGA) 0/1 (clear or almost clear skin) at week 16, with a significantly greater Psoriasis Area and Severity Index (PASI) 75 response rate seen as early as w
Merz Completes Inaugural €450 Million Schuldschein Loan Issuance17.7.2026 00:36:00 EEST | Press release
The Merz Group has successfully completed its first-ever Schuldschein loan issuance, placing a total volume of €450 million in the debt capital market – a multiple of three relating to the launch volume. The debut transaction was significantly oversubscribed and attracted strong interest from all investor groups. The proceeds were settled and paid out today. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260716926041/en/ Dr. Almuth Steinkühler, Chief Financial Officer Merz Group The transaction comprises both fixed- and floating-rate tranches with maturities of three, five, seven, and ten years. Around 50 German and international investors participated, representing a broad range of institutions, including private banks, German federal state-owned banks, public savings banks, cooperative banks, pension funds and occupational pension institutions. With the successful placement, Merz has further diversified its funding base by
The Estée Lauder Companies Appoints Madeleine Boyd as Senior Vice President, Global Brand Communications16.7.2026 23:22:00 EEST | Press release
The Estée Lauder Companies Inc. (NYSE: EL) today announced the appointment of Madeleine Boyd as Senior Vice President, Global Brand Communications, effective July 20, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260716738393/en/ Photo by Esteban La Tessa As part of the company’s continued efforts to strengthen how its brands better connect with consumers, Ms. Boyd will establish and lead a newly integrated Global Brand Communications team. In this role, she will ensure the company’s diverse portfolio is anchored by a cohesive enterprise communications strategy, while accelerating bold, consumer-first storytelling that drives earned media, cultural relevance, and brand desirability. She will also strengthen creator engagement, helping the company’s brands gain attention where culture is being shaped. Ms. Boyd brings extensive experience spanning brand strategy, communications, consumer engagement, and cultural insight
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom